Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

用于莱姆病快速血清诊断的芯片即时检测实验室

• 批准号: 9052111
• 负责人: Maria Gomes-Solecki
• 金额: $ 100万
• 依托单位: IMMUNO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-03 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9052111
• 关键词: Affect; Aftercare; Algorithms; Antibiotics; Antibodies; Antigens; Area; Arthritis; Bedside Testings; Biological Assay; Biological Markers; Blood; Blood Volume; Borrelia burgdorferi; Caring; Centers for Disease Control and Prevention (U.S.); Collaborations; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease Outcome; Disease Progression; Early Diagnosis; Early treatment; Enzyme-Linked Immunosorbent Assay; Extramural Activities; Fingers; Health; Heart; Human; In Vitro; Injury; Joints; Laboratories; Lead; Letters; Lyme Disease; Microfluidics; Nervous system structure; Phase; Refractory; Reproducibility; Running; Sensitivity and Specificity; Serodiagnoses; Serological; Serum; Skin; Staging; Symptoms; Syndrome; System; Technology; Testing; Time; United States; Validation; Vector-transmitted infectious disease; base; body system; cost; cross reactivity; design; improved; micro-total analysis system; outcome forecast; performance tests; point of care; polypeptide; prevent; prototype; standard of care; validation studies; Affect; Aftercare; Algorithms; Antibiotics; Antibodies; Antigens; Area; Arthritis; Bedside Testings; Biological Assay; Biological Markers; Blood; Blood Volume; Borrelia burgdorferi; Caring; Centers for Disease Control and Prevention (U.S.); Collaborations; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease Outcome; Disease Progression; Early Diagnosis; Early treatment; Enzyme-Linked Immunosorbent Assay; Extramural Activities; Fingers; Health; Heart; Human; In Vitro; Injury; Joints; Laboratories; Lead; Letters; Lyme Disease; Microfluidics; Nervous system structure; Phase; Refractory; Reproducibility; Running; Sensitivity and Specificity; Serodiagnoses; Serological; Serum; Skin; Staging; Symptoms; Syndrome; System; Technology; Testing; Time; United States; Validation; Vector-transmitted infectious disease; base; body system; cost; cross reactivity; design; improved; micro-total analysis system; outcome forecast; performance tests; point of care; polypeptide; prevent; prototype; standard of care; validation studies

DESCRIPTION: Caused by Borrelia burgdorferi, Lyme disease (LD) can affect the skin, heart, joints or nervous system leading to an array of largely non-specific symptoms that overlap with those of other debilitating illnesses. Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic-refractory arthritis or Post- Treatment Lyme disease Syndrome (PTLDS). Early diagnosis and treatment is key to improving disease outcomes. Current assays do not discriminate between early and late stages of the disease and cannot predict prognosis. We propose to use ultrasensitive microfluidics technology to develop the first quantitative rapid lab-on-a-chip point of care (POC) assay for the serodiagnosis of Lyme disease. The proposed POC test will provide sensitive and definitive detection and differentiation of early- and late- stage Lyme disease in a single test. It is a versatile and informative first-tier assay which can evolve to replace the current bi-serologic two-tier standard of care.

描述：由Borrelia burgdorferi引起的，莱姆病（LD）会影响皮肤，心脏，关节或神经系统，导致一系列非特异性症状与其他令人衰弱的疾病重叠。疾病的进展会导致患有不利预后的疾病，例如抗生素 - 难治性关节炎或治疗后莱姆病综合征（PTLDS）。早期诊断和治疗是改善疾病预后的关键。当前的测定不能区分疾病的早期和晚期，无法预测预后。我们建议使用超敏感的微流体技术来开发第一个定量的快速实验室护理点（POC）测定莱姆病的症状。拟议的POC测试将在单个测试中提供对早期和晚期莱姆病的敏感和确定性检测和分化。这是一种多功能且内容丰富的第一层测定法，可以进化以取代当前的双层两层标准 照顾。